Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms
A Phase 1, Open-Label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of PF-00562271 In Patients With Advanced Non-Hematologic Malignancies
Sponsor: Verastem, Inc.
Listed as NCT00666926, this PHASE1 trial focuses on Head and Neck Neoplasm and Pancreatic Neoplasm and remains completed. Sponsored by Verastem, Inc., it has been updated 7 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Dec 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Verastem, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .